CD30 is a survival factor and a biomarker for transformed human pluripotent stem cells

被引:115
|
作者
Herszfeld, D
Wolvetang, E
Langton-Bunker, E
Chung, TL
Filipczyk, AA
Houssami, S
Jamshidi, P
Koh, K
Laslett, AL
Michalska, A
Nguyen, L
Reubinoff, BE
Tellis, I
Auerbach, JM
Ording, CJ
Looijenga, LHJ
Pera, MF
机构
[1] Monash Univ, Med Res Inst, Clayton, Vic 3800, Australia
[2] Australian Stem Cell Ctr, Clayton, Vic 3800, Australia
[3] Amer Type Culture Collect, Stem Cell Ctr, Manassas, VA 20110 USA
[4] Erasmus Univ, Med Ctr, Dr Daniel Den Hoed Canc Ctr, Josephine Nefkens Inst,Lab Exp Patho Oncol, NL-3000 DR Rotterdam, Netherlands
关键词
D O I
10.1038/nbt1197
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The application of human embryonic stem (hES) cells in regenerative medicine will require rigorous quality control measures to ensure the safety of hES cell-derived grafts. During propagation in vitro, hES cells can acquire cytogenetic abnormalities(1-3) as well as submicroscopic genetic lesions, such as small amplifications or deletions(4). Many of the genetic abnormalities that arise in hES cell cultures are also implicated in human cancer development. The causes of genetic instability of hES cells in culture are poorly understood, and commonly used cytogenetic methods for detection of abnormal cells are capable only of low-throughput analysis on small numbers of cells. The identification of biomarkers of genetic instability in hES cells would greatly facilitate the development of culture methods that preserve genomic integrity. Here we show that CD30, a member of the tumor necrosis factor receptor superfamily, is expressed on transformed but not normal hES cells, and that CD30 expression protects hES cells against apoptosis.
引用
收藏
页码:351 / 357
页数:7
相关论文
共 50 条
  • [1] CD30 is a survival factor and a biomarker for transformed human pluripotent stem cells
    Daniella Herszfeld
    Ernst Wolvetang
    Emma Langton-Bunker
    Tung-Liang Chung
    Adam A Filipczyk
    Souheir Houssami
    Pegah Jamshidi
    Karen Koh
    Andrew L Laslett
    Anna Michalska
    Linh Nguyen
    Benjamin E Reubinoff
    Irene Tellis
    Jonathan M Auerbach
    Carol J Ording
    Leendert H J Looijenga
    Martin F Pera
    Nature Biotechnology, 2006, 24 : 351 - 357
  • [2] Amyloid Precursor Protein Is a Biomarker for Transformed Human Pluripotent Stem Cells
    Venkataramani, Vivek
    Thiele, Knut
    Behnes, Carl Ludwig
    Wulf, Gerald G.
    Thelen, Paul
    Opitz, Lennart
    Salinas-Riester, Gabriella
    Wirths, Oliver
    Bayer, Thomas A.
    Schweyer, Stefan
    AMERICAN JOURNAL OF PATHOLOGY, 2012, 180 (04): : 1636 - 1652
  • [3] CD 30 is a marker of undifferentiated human embryonic stem cells rather than a biomarker of transformed hESCs
    Lagarkova, Maria A.
    Volchkov, Pavel Y.
    Philonenko, Elena S.
    Pfannkuche, Kurt
    Prokhorovich, Maria A.
    Zabotina, Tatyana
    Hescheler, Juergen
    Kiselev, Sergei L.
    CELL CYCLE, 2008, 7 (22) : 3610 - 3612
  • [4] Ascorbate Promotes Epigenetic Activation of CD30 in Human Embryonic Stem Cells
    Chung, Tung-Liang
    Turner, Jennifer P.
    Thaker, Nilay Y.
    Kolle, Gabriel
    Cooper-White, Justin J.
    Grimmond, Sean M.
    Pera, Martin F.
    Wolvetang, Ernst J.
    STEM CELLS, 2010, 28 (10) : 1782 - 1793
  • [5] Is CD30 a predictive biomarker for brentuximab vedotin?
    Chen, Robert
    LEUKEMIA & LYMPHOMA, 2017, 58 (07) : 1524 - 1525
  • [6] Skin stem cells transformed into pluripotent stem cells
    不详
    ATLA-ALTERNATIVES TO LABORATORY ANIMALS, 2007, 35 (06): : 551 - 551
  • [7] Ki67 and CD30 Predict Survival in Non-Transformed Mycosis Fungoides
    Edinger, J. T.
    Clark, B. Z.
    Pucevich, B. E.
    Geskin, L. J.
    Swerdlow, S. H.
    LABORATORY INVESTIGATION, 2009, 89 : 261A - 261A
  • [8] Ki67 and CD30 Predict Survival in Non-Transformed Mycosis Fungoides
    Edinger, J. T.
    Clark, B. Z.
    Pucevich, B. E.
    Geskin, L. J.
    Swerdlow, S. H.
    MODERN PATHOLOGY, 2009, 22 : 261A - 261A
  • [9] Amyloid Precursor Protein Is a Biomarker for Transformed Human Pluripotent Stem Cells (vol 180, pg 1636, 2012)
    Venkataramani
    AMERICAN JOURNAL OF PATHOLOGY, 2012, 181 (01): : 374 - 374
  • [10] Immunologic Targeting of CD30 Eliminates Tumorigenic Human Pluripotent Stem Cells (iPSC) Allowing Safer Clinical Application of hiPSC-Based Therapy
    Sougawa, Nagako
    Masuda, Shigeo
    Miyagawa, Shigeru
    Fukushima, Satsuki
    Ito, Emiko
    Saito, Atsuhiro
    Sawa, Yoshiki
    CIRCULATION, 2014, 130